Varsetatug masetecan

Varsetatug masetecan (CX-2051, Varseta-M) is a masked antibody-drug conjugate (Probody ADC, topoisomerase-1 inhibitor payload) from CytomX Therapeutics. A masked, conditionally activated antibody-drug conjugate directed at EpCAM that carries a topoisomerase-1 inhibitor payload. Its furthest stage is phase 1, for metastatic colorectal cancer. ClinicalTrials.gov registers it in 2 studies linked below. Phase 1 dose expansion in colorectal cancer (NCT06265688); combination study NCT07900165 not yet recruiting. FDA Fast Track for relapsed/refractory metastatic colorectal cancer (27 August 2026). Whether it works in people has not been established unless a trial below reports it.